A Phase 1/2 interventional study of ION582 in Angelman Syndrome, sponsored by Ionis Pharmaceuticals, Inc.. Active, not recruiting at 11 sites in 6 countries. Open to participants aged 0 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Ionis Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Angelman Syndrome with a site in United States — 6 open to participants now, 10 under way, 3 of them phase 3. Angelman Syndrome · United States.
Among the 33 studies in Angelman Syndrome with a site in United States, this one is the 13th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2021, is one of 3 in phase 1/2, and was the 21st registered.
52 studies on the registry are indexed under Angelman Syndrome; 16 are open to participants now.
Browse Angelman Syndrome studies →6 of the 33 studies in Angelman Syndrome with a site in United States are open now. Recruiting first, the newest first:
Ionis Pharmaceuticals, Inc. · Sites in United States
Ages 2–50
Massachusetts General Hospital · Sites in United States
Ages 1+
OHB Pediatrics Ltd. · Sites in United States, Korea, Republic of, Taiwan
Ages 1–50
MavriX Bio, LLC · Sites in United States
Ages 4–50
Boston Children's Hospital · Sites in United States, Canada
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Angelman Syndrome studies recruiting now, 6 (43%) set no upper age limit and 7 (50%) stop at 75 or younger; 14 take children under 18; none take healthy volunteers.
This study: 0 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 9
First in 1999; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 71 is close to the median of 66 across 29 interventional studies indexed under Angelman Syndrome.
Median enrollment 73 across the 24 interventional studies, 300 across the 9 observational. Of the 23 that completed or were terminated, 8 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 33 have an industry lead sponsor. The 10 most frequent:
Ionis Pharmaceuticals, Inc. is the lead sponsor of 118 studies on the registry; 10 are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 22 (45%) have results posted.
Ionis Pharmaceuticals, Inc. has 3 studies filed under Angelman Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Angelman Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914609Phase 3Ionis Pharmaceuticals, Inc.REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome | 2027-08 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06139172Rush University Medical CenterWeb Intervention for Parents of Youth With Genetic Syndromes (WINGS) | 2026-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 33 studies in Angelman Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of ascending doses of ION582 administered intrathecally in participants with Angelman syndrome.
This is a Phase 1-2a, open-label study consisting of 3 parts in approximately 70 participants. Part 1 is a multiple ascending dose (MAD) study, consisting of a 13-week MAD Treatment Period and a minimum 12-week Post-MAD Follow-Up Period. Part 2 is a multi-center 49-week study where participants who completed Part 1 will receive IT bolus doses of ION582 followed by a minimum 12-week Part 2 follow up period. Part 3 extends the treatment period for participants who completed Part 2 for up to an additional 3 years followed by a 32-week post-LTE follow up period.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ION582 will be administered as IT injection over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
Drug: ION582
ION582 will be administered as IT injection over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
Drug: ION582
ION582 will be administered as IT injection over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
Drug: ION582
ION582 will be administered as IT injection over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
Drug: ION582
ION582 will be administered as IT injection of over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
Drug: ION582
ION582 will be administered as IT injection over a period of 13 weeks, with a minimum of approximately 12 weeks between each dose administration.
Drug: ION582
ION582 will be administered as IT injection of over a period of 49 weeks, with additional dosing intervals.
Drug: ION582
ION582 will be administered as IT injection of over a period of 49 weeks, with additional dosing intervals.
Drug: ION582
ION582 will be administered as IT injection of over a period of 145 weeks, with additional dosing intervals.
Drug: ION582
ION582 will be administered as IT injection of over a period of 145 weeks, with additional dosing intervals.
Drug: ION582
ION582 will be administered by IT injection.
To evaluate the safety and tolerability of single and multiple doses of ION582 (incidence, severity, and dose-relationship of adverse effects and changes in the laboratory parameters).
The safety and tolerability of ION582 will be assessed by determining the incidence, severity, and dose relationship of adverse effects and changes in the laboratory parameters by dose.
Time frame: Part 1: Up to Week 45; Part 2: Up to Week 81
Maximum Observed Plasma Concentration (Cmax) of ION582
Time frame: Part 1: Up to Week 45; Part 2: Up to Week 81
Time to Reach Maximal Plasma Concentration (Tmax) of ION582
Time frame: Part 1: Up to Week 45; Part 2: Up to Week 81
Plasma Elimination Half-Life (t1/2λz) of ION582
Time frame: Part 1: Up to Week 45; Part 2: Up to Week 81
Concentration ION582 in CSF
Time frame: Part 1: Up to Week 13; Part 2: Up to Week 49
Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Dec 2021 (actual). Primary completion is estimated for Mar 2029, 87 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.